Ranbaxy Laboratories has informed BSE that the company is currently examining processes and controls at all its Active Pharmaceutical Ingredients (API) manufacturing and quality units. This action has led to temporarily putting on hold shipments from the company’s API facilities of the Toansa and Dewas plants.
According to a note to the BSE, this voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the company to assess and review the processes and controls. The company will resume shipments after reassuring them about the processes and controls at these facilities.
In the meanwhile, a committee of the board has been recently constituted this month as the “Quality & Integrity Committee”. The Committee’s objective is to help and assure good governance to all Ranbaxy stakeholders. Its primary role is to provide oversight on the company’s manufacturing and quality operations, systems, organisation and integrity.
EP News Bureau– Mumbai
- Advertisement -
